Last mentioned: Feb 24, 2026
Earnings Release
Both EVH and LAB report full-year 2025 financial results to the market.
Asset Realignment
Standard BioTools completes a significant acquisition/disposition of assets per SEC filings.
Operational Update
Standard BioTools provides preliminary 2025 performance data and strategic outlook.
SomaLogic Merger
Standard BioTools completes merger with SomaLogic to expand proteomics capabilities.
Evolent and Standard BioTools reported strong 2025 revenue growth, with Evolent crossing the $2.6 billion threshold and Standard BioTools achieving its first positive adjusted EBITDA quarter. Both companies are now pivoting toward margin expansion and operational discipline as they enter the 2026 fiscal year.
Standard BioTools and Evolent Health reported their full-year 2025 financial results, marking a critical milestone in their respective paths toward operational efficiency and market expansion. The reports highlight a year defined by strategic integration for Standard BioTools and continued momentum in value-based care for Evolent.
Standard BioTools and Evolent Health released their Q4 and full-year 2025 financial results, marking a critical inflection point for both the life sciences tools and value-based care sectors. The reports highlight a focus on operational efficiency and the integration of large-scale acquisitions as both companies navigate a complex macroeconomic environment.
Evolent and Standard BioTools reported Q4 and full-year 2025 financial results, highlighting a sector-wide shift toward operational efficiency and consolidation. While Evolent scales its specialty care management platform, Standard BioTools is navigating the final stages of its SomaLogic integration amidst a complex life sciences market.